Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. BioCryst Pharmaceuticals Inc. shares valued at $55,200 were sold by ABERCROMBIE GEORGE B on Apr 18. At $11.04 per share, ABERCROMBIE GEORGE B sold 5,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Thackray Helen M. sold 7,600 shares, netting a total of over 123,120 in proceeds. Following the sale of shares at $16.20 each, the insider now holds 136,400 shares.
Before that, Sheridan William P had sold 161,139 shares from its account. In a trade valued at $2,719,493, the Chief Medical Officer traded BioCryst Pharmaceuticals Inc. shares for $16.88 each. Upon closing the transaction, the insider’s holdings decreased to 161,139 shares, worth approximately $0.36 million.
As published in a research note from Barclays on April 18, 2022, BioCryst Pharmaceuticals Inc. [BCRX] has been rated down from an Overweight to an Equal weight and the price target has been revised to $13 from $22. This represents a 27.0% premium over Wednesday’s closing price. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in mid April. As of December 10, 2021, Oppenheimer has initiated its “an Outperform” rating for BCRX. Earlier on August 06, 2021, Jefferies downgraded its rating. Their new recommendation was “a Hold” for BCRX stock which previously was a “a Buy”.
Analyzing BCRX’s Price Performance
On Wednesday, BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] rose 0.42% to $9.49. The stock’s lowest price that day was $9.19, but it reached a high of $9.805 in the same session. During the last five days, there has been a surge of approximately 0.42%. Over the course of the year, BioCryst Pharmaceuticals Inc. shares have dropped approximately -31.48%. Shares of the company reached a 52-week high of $19.99 on 02/16/22 and a 52-week low of $7.61 on 05/12/22. A 50-day SMA is recorded $9.62, while a 200-day SMA reached $13.45. Nevertheless, trading volume fell to 2.83 million shares from 2.99 million shares the previous day.
Support And Resistance Levels for BioCryst Pharmaceuticals Inc. (BCRX)
According to the 24-hour chart, there is a support level at 9.18, which, if violated, would cause prices to drop to 8.88. In the upper region, resistance lies at 9.80. The next price resistance is at 10.11. RSI (Relative Strength Index) is 47.19 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.38, which suggests the price will decrease in the coming days. Percent R is at 65.83%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of BioCryst Pharmaceuticals Inc. (BCRX)?
According to The Vanguard Group, Inc. filings, the company currently owns 12,904,660 shares, which is about 6.95% of the total BCRX shares outstanding. The investor’s shares have appreciated by 3,812,280 from its previous 13-F filing of 9092380.0 shares. With the completion of the sale, Baker Bros. Advisors LP’s stake is now worth $118,337,716. BlackRock Fund Advisors reduced a -2.89% interest valued at $113.9 million while SSgA Funds Management, Inc. sold a -786,277 stake. A total of 51,639 shares of BioCryst Pharmaceuticals Inc. were sold by Pictet Asset Management SA during the quarter, and 3,263,983 were bought by Fidelity Management & Research Co. In its current portfolio, Fisher Asset Management LLC holds 3,986,823 shares valued at $37.12 million.
In terms of BioCryst Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $17.08 in the next 12 months, up nearly 42.86% from the previous closing price of $9.45. Analysts anticipate BioCryst Pharmaceuticals Inc. stock to reach $30.00 by 2022, with the lowest price target being $11.00. In spite of this, 13 analysts ranked BioCryst Pharmaceuticals Inc. stock as an Overweight at the end of 2022. On August 03, 2021, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $21.